FTSE 250 movers: Charter Court and Onesavings buoyant on merger news
11th Mar 2019 15:05
(Sharecast News) - London's FTSE 250 was up 0.06% at 19,058.77 in afternoon trade on Monday, as merger news fuelled the index's rise.
Read moreTobacco stocks rise after FDA boss Gottlieb quits
6th Mar 2019 09:20
(Sharecast News) - Shares in tobacco companies rose on Wednesday after America's chief drug and tobacco regulator unexpectedly resigned overnight.
Read moreIndivior launches schizophrenia treatment in US
27th Feb 2019 13:22
(Sharecast News) - Indivior has launched its monthly injectable treatment for adult schizophrenia in the US, for which it has guided to peak sales of $200-300m.
Read moreIndivior to release generic version of opioid drug after losing court battle
20th Feb 2019 07:40
(Sharecast News) - Indivior said it was releasing an authorised generic version of its Suboxone opiod addiction treatment in the US after losing a court bid to stop a copycat version made by India-based rival Dr. Reddy's Laboratories.
Read moreIndivior upbeat on publication of Sublocade data
19th Feb 2019 09:47
(Sharecast News) - Indivior shared data from its phase-three clinical trial evaluating the efficacy, safety and tolerability of its new 'Sublocade' buprenorphine extended-release injectable treatment for opioid addiction, which were published by peer-reviewed medical journal The Lancet.
Read moreIndivior unable to provide guidance amid Suboxone uncertainty
14th Feb 2019 09:33
(Sharecast News) - Indivior said it was unable to give investors an indication of revenue and profit for the current year due to uncertainty about how its star drug will affect by copycat versions.
Read moreIndivior applies to Supreme Court to block generic rivals
12th Feb 2019 07:26
(Sharecast News) - Indivior said it will petition the US Supreme Court to block a decision by the Court of Appeals of the Federal Circuit to allow other companies to sell their generic versions of its anti-opioid treatment.
Read moreIndivior set for losses after US legal defeat
5th Feb 2019 07:42
(Sharecast News) - Anti-opioid drugmaker Indivior warned on Tuesday it could lose 80% of market share "in a matter of months" to generic versions of its Suboxone drug, after a court defeat in its long-running effort to stop generic competitors entering the market.
Read moreIndivior strikes truce with Alvogen, sells China tablet rights
4th Feb 2019 07:18
(Sharecast News) - Indivior has agreed to sell the Chinese rights to a tablet version of its opioid addiction treatment for $122.5m and also said it had entered into an agreement with Alvogen Pine Brook to temporarily prevent it entering the sublingual film market in the US.
Read moreIndivior wins US restraining order against Alvogen
25th Jan 2019 07:29
(Sharecast News) - Pharmaceutical company Indivior said the New Jersey District Court had granted it a temporary restraining order (TRO) that prevents rival Alvogen from launching generic versions of its opioid addiction treatment.
Read moreSunday share tips: Indivior, Team 17, 3i Infrastructure, Motif Bio
30th Dec 2018 16:21
(Sharecast News) - In her 'Inside the City' column for the Sunday Times this week, Sabah Meddings looked back on the year that was for Indivior - the FTSE 250 firm that has seen its share price fall and fall again as it fights for the right to exclusively sell its 'Suboxone' film treatment for opioid addicts.
Read moreFTSE 250 movers: Hikma slips but JD Sports sprints ahead
21st Dec 2018 15:15
(Sharecast News) - London's FTSE 250 was down 0.36% at 17,384.94 in afternoon trade on Friday, with international transport operator Stagecoach dropping on the back of a broker note.
Read moreIndivior shares rise on publication of RECOVER study design
20th Dec 2018 09:38
(Sharecast News) - Indivior announced the publication of the study design and participant characteristics of the 'RECOVER' (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) study in the 'Contemporary Clinical Trials' journal on Thursday.
Read moreIndivior recuperates after confirming full year targets
18th Dec 2018 12:57
(Sharecast News) - Indivior said it expects to hit its full-year targets, boosted by higher than expected sales for its new longer-lasting opioid addiction treatment.
Read moreFTSE 250 movers: G4S sinks but Indivior rises on courtroom drama
14th Dec 2018 14:39
(Sharecast News) - London's FTSE 250 was down 0.84% at 17,669.60 in afternoon trade on Friday, with G4S leading the fallers as its share price levelled out following a Thursday jump.
Read more